Mary Kay Ladone - Jun 16, 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Director
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Jun 16, 2022
Transactions value $
$0
Form type
4
Date filed
6/22/2022, 08:39 PM
Previous filing
Jun 10, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A common stock Options Exercise $0 +1.81K $0.00 1.81K Jun 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -1.81K -33.33% $0.00 3.63K Jun 16, 2022 Class A Common Stock 1.81K Direct F1, F2
transaction BVS Restricted Stock Units Award $0 +16.6K $0.00 16.6K Jun 17, 2022 Class A Common Stock 16.6K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 The remaining RSUs shall vest and become exercisable in two approximately equal installments on June 16, 2023 and June 16, 2024, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date.
F3 The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date.